-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 15th, a team of two teams from the Shanghai Institute of Pharmacy of the Chinese Academy of Sciences and the Institute of Pharmacology at Monash University in Australia published the study of two distinct domains of the glucagon-like peptide-1 receptor-peptide-mediated-biasenism in The Journal of Biology.
G protein conjugate receptor is a family of membrane proteins with seven transmembrane structures, glucagon-like peptide-1 receptors belong to the B1 type, for the treatment of type 2 diabetes and obesity, has been listed in the receptor excited drugs including eseninatide, liraglutide and dalate, such as nearly ten, annual sales of more than 10 billion U.S. dollars.
the different frequency, clinical efficacy, adverse reactions and tolerances shown by these drugs were closely related to the bias exagoglyceeffect effect of glucagon-like peptide-1.
bias agoginiation refers to the binding of different agonists and receptors to make different changes in their composition and to conjugate different effect proteins, thus activating different signaling pathways or preferences to activate a signaling pathway, which in turn produces different biological effects.
the N-end of the glucagon-like peptide-1 receptor and the first transmembrane helical near-cell outer domain in its activation process are dynamically changing and extremely unstable, and are missing in many parsed crystals or frozen electron mirror s3D structures, and there is a lack of understanding of the role of related amino acid sites.
in order to break through this problem, the Shanghai Drug Institute's Wang Mingwei team and the Australian Monash University Patrick Sexton and Denise Wootten team began three years ago to organize a joint attack, the receptor N end and the first transmembrane helix near-cell domain of 28 amino acids fixed-point mutation, using a variety of technical systems to study the activation of a variety of peptide ligands to receptors and forces and different signal ingestive pathways (cAMP, pERK1/2 and Ca2. The results of the
show that the different amino acid sites on the pancreatic glycemic peptide-1 receptor regulate the affinity of the ligand and the signaling pathways it activates, and there are common already characteristics between the ligands and between the signaling pathways, indicating that the domain plays an important role in regulating signal bias transduction, thus providing a new way of thinking for the design of beneficial harm-avoiding drugs based on the principle of receptor bias agitation.
the research was supported by the Australian National Health and Medical Research Council, the National Natural Science Foundation, the Chinese Academy of Sciences Strategic Pilot Science and Technology Special And Shanghai Science and Technology Development Fund, and the first author of the paper, Wang Mingwei, a doctoral student, lei Saifei, went to Australia to study with the support of the Joint Training Program of Doctoral Students of the Chinese Academy of Sciences.
.